Published: May 13, 2021
Mary Newman, former SVP of Regulatory Affairs at Astellas Gene Therapies, joins Taysha with over 30 years of experience in regulatory affairs and research and development in the biotech industry
Extensive experience deeply rooted in gene therapy at Astellas Gene Therapies, Audentes Therapeutics and BioMarin
DALLAS (BUSINESS WIRE) Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the most recent addition to its leadership team with the appointment of industry veteran Mary Newman as Chief Development Officer. Ms. Newman will oversee program and portfolio management, as well as translational sciences, and will report to Suyash Prasad, MBBS, M.Sc., MRCP, MRCPCH, FFPM, Taysha’s Chief Medical Officer
Suyash-prasad
Development-officer
Bayer-healthcare-pharmaceuticals-inc
Head-of-research
Shire-ltd
Regulatory-affairs
Nasdaq
Berlex-inc
Regulatory-affairs-at-biomarin-pharmaceutical-inc
Taysha-gene-therapies-inc
Regulatory-affairs-at-astellas-gene-therapies
Sarcode-bioscience-inc